
Mark A. Meltz
San Francisco-based biotech company Audentes Therapeutics has announced the appointment of Mark A. Meltz as the company’s first general counsel.
Audentes CEO Matthew R. Patterson said Meltz is an experienced leader “with significant industry and subject matter expertise which will be invaluable as we continue to advance our portfolio of product candidates through clinical and regulatory milestones and build a commercial organization...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In